Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol. 2003;42:234 40. 449. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascular- ization before elective major vascular surgery. N Engl J Med. 2004;351: 2795 804. 450. Schouten O, van Kuijk JP, Flu WJ, et al. Long-term outcome of pro- phylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V Pilot Study). Am J Cardiol. 2009;103:897 901. 451. Kaluza GL, Joseph J, Lee Jr, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35: 1288 94. 452. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007; 297:2001 9. 453. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008;359:1330 42. Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e631 453a.Mehilli J, Pache J, Abdel-Wahab M, et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet. 2011: published online before print August 28, 2011, doi:10.1016/S0140-6736(11)61255-5. 454. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315 23. 455. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942 7. 456. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009; 360:1946 59. 457. Pan XH, Chen YX, Xiang MX, et al. 